Cabaletta Bio (NASDAQ:CABA) released its quarterly earnings results on Sunday. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.05, MarketWatch Earnings reports.
NASDAQ CABA traded down $0.33 on Tuesday, reaching $10.39. 445,218 shares of the stock were exchanged, compared to its average volume of 111,678. Cabaletta Bio has a one year low of $6.35 and a one year high of $16.38. The firm has a market capitalization of $209.30 million, a PE ratio of -7.58 and a beta of 1.67. The company’s 50-day simple moving average is $11.07 and its two-hundred day simple moving average is $12.48.
Several analysts recently issued reports on CABA shares. HC Wainwright boosted their target price on shares of Cabaletta Bio from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, March 23rd. Chardan Capital reissued a “buy” rating and set a $21.00 price objective on shares of Cabaletta Bio in a research report on Friday, January 8th. Finally, Zacks Investment Research cut Cabaletta Bio from a “buy” rating to a “hold” rating in a report on Monday, January 4th.
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
Featured Story: What is the Hang Seng index?
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.